All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Shijiazhuang Discovery Medicine Technology Co. Ltd. has divulged nucleotides reported to be useful for the treatment of cardiovascular and cerebrovascular disorders.
I-Cordis LLC has been awarded a phase II Small Business Innovation Research (SBIR) grant for US$1,548,708 from the National Heart, Lung, and Blood Institute (NHLBI) to further develop a potential immune-modulatory treatment for heart failure with preserved ejection fraction (HFpEF).
Atrial fibrillation (AF) is a very common diagnosed arrhythmia and catheter ablation is an effective treatment, but recurrence occurs after catheter ablation and remains a medical challenge. MicroRNAs can be easily detected in the circulation, and they are epigenetic regulators in many biological processes; their usefulness as biomarkers of risk stratification in patients with AF was investigated.
Researchers from University Hospital Bonn presented data from a study that aimed to evaluate the significance of serum levels of the endoplasmic-reticulum-stress chaperone GRP78 in patients undergoing coronary angiography for suspected coronary artery disease (CAD).
There is a lack of biomarkers for disease activity in aortic stenosis (AS). On the other hand, citrullination is involved in many chronic inflammatory processes and citrullinated proteins have been found within atherosclerotic plaque.
GSK plc presented data on the discovery of a selective and potent lead series for G protein-coupled receptor kinase 2 (GRK2) inhibition for the potential treatment of heart failure. Heart failure remains a leading cause of morbidity and mortality worldwide.
Southern Marine Science and Engineering Guangdong Laboratory and Guangdong Medical University have disclosed peptides acting as angiotensin-converting enzyme (ACE) inhibitors reported to be useful for the treatment of hypertension.
Rhizen Pharmaceuticals and Incozen Therapeutics have synthesized new cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of atherosclerosis, autoimmune disease, cancer, Alzheimer's disease, pulmonary fibrosis, inflammatory disorders, psoriasis and rheumatoid arthritis, among other disorders.
Using a knock-in mouse model of Brugada syndrome (BrS) with an SCN5A mutation identified in multiple BrS families (Scn5aG1746R/+), a team of scientists from various research institutions evaluated the effects of upregulation of MOG1 (ran guanine nucleotide release factor, RanGNRF) via adeno-associated virus serotype 9 (AAV9) vector delivery on BrS features.
RSS
